Erythropoietin: physiology and clinical applications. NLM AIDSLINE Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Erythropoietin: physiology and clinical applications.

Blood Cell Growth Factors: Their Present and Future Use in Hematology and Oncology. Murphy MJ Jr, ed. Dayton, OH, AlphaMed Press, p. 105-20, 1991.. Unique Identifier : AIDSLINE ICDB/93689909
Spivak JL; Dept. of Medicine, Johns Hopkins Univ. Sch. of Medicine,; Baltimore, MD

Abstract: Recombinant human erythropoietin (rhEpo) has come of age. Clinical trials have substantiated that the hormone can alleviate transfusion requirements, correct anemia and improve the quality of life in patients (pts) with end-stage renal disease. Epo is also effective in correcting anemia in pts with rheumatoid arthritis, in AIDS pts taking zidovudine and in pts with various malignancies both off and on chemotherapy. Autologous blood donors are able to donate more blood with less of a deficit in RBC mass when receiving Epo, and preliminary studies suggest that Epo may have a role in correcting the anemia of prematurity. The most cost effective and promising role for the hormone, apart from its use in pts with end-stage kidney disease, is likely to be in the prevention of the need for homologous blood transfusion in a variety of clinical situations, such as the perisurgical period, the anemia associated with prematurity, the period following bone marrow transplantation, and in anticipation of various forms of chemotherapy or retroviral therapy.
Keywords: Acquired Immunodeficiency Syndrome/COMPLICATIONS/DRUG THERAPY Anemia/COMPLICATIONS/THERAPY Arthritis, Rheumatoid/THERAPY Bone Marrow Transplantation Clinical Trials Erythropoietin/*PHYSIOLOGY/THERAPEUTIC USE Human Infant, Premature Kidney Failure, Chronic/*THERAPY Neoplasms/THERAPY Recombinant Proteins/THERAPEUTIC USE Zidovudine/THERAPEUTIC USE MEETING PAPERKWDacquiredimmunodeficiencysyndrome/complications/drugtherapyanemia/complications/therapyarthritis,rheumatoid/therapybonemarrowtransplantationclinicaltrialserythropoietin/KWDphysiology/therapeuticusehumaninfant,prematurekidneyfailure,chronic/KWDtherapyneoplasms/therapyrecombinantproteins/therapeuticusezidovudine/therapeuticusemeetingpaper
930530
M9350997

Copyright © 1993 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .